全文获取类型
收费全文 | 100325篇 |
免费 | 9229篇 |
国内免费 | 6970篇 |
专业分类
耳鼻咽喉 | 908篇 |
儿科学 | 1137篇 |
妇产科学 | 746篇 |
基础医学 | 9530篇 |
口腔科学 | 1785篇 |
临床医学 | 12585篇 |
内科学 | 12608篇 |
皮肤病学 | 820篇 |
神经病学 | 4447篇 |
特种医学 | 4191篇 |
外国民族医学 | 44篇 |
外科学 | 10501篇 |
综合类 | 22480篇 |
现状与发展 | 26篇 |
一般理论 | 3篇 |
预防医学 | 7901篇 |
眼科学 | 2463篇 |
药学 | 10598篇 |
88篇 | |
中国医学 | 6685篇 |
肿瘤学 | 6978篇 |
出版年
2024年 | 279篇 |
2023年 | 1256篇 |
2022年 | 3077篇 |
2021年 | 4192篇 |
2020年 | 3371篇 |
2019年 | 2775篇 |
2018年 | 2856篇 |
2017年 | 2985篇 |
2016年 | 2629篇 |
2015年 | 4262篇 |
2014年 | 5398篇 |
2013年 | 5600篇 |
2012年 | 8129篇 |
2011年 | 8641篇 |
2010年 | 6299篇 |
2009年 | 5461篇 |
2008年 | 6155篇 |
2007年 | 6131篇 |
2006年 | 5807篇 |
2005年 | 5247篇 |
2004年 | 4144篇 |
2003年 | 4420篇 |
2002年 | 3690篇 |
2001年 | 2933篇 |
2000年 | 2282篇 |
1999年 | 1790篇 |
1998年 | 1058篇 |
1997年 | 1117篇 |
1996年 | 822篇 |
1995年 | 684篇 |
1994年 | 624篇 |
1993年 | 349篇 |
1992年 | 391篇 |
1991年 | 352篇 |
1990年 | 298篇 |
1989年 | 249篇 |
1988年 | 214篇 |
1987年 | 174篇 |
1986年 | 128篇 |
1985年 | 93篇 |
1984年 | 45篇 |
1983年 | 24篇 |
1982年 | 38篇 |
1981年 | 21篇 |
1980年 | 8篇 |
1979年 | 13篇 |
1965年 | 2篇 |
1940年 | 3篇 |
1935年 | 2篇 |
1934年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
22.
目的探讨1 470 nm激光剜除治疗高危前列腺增生的手术技巧及临床效果。
方法回顾分析2018年6月至2018年9月中山大学附属第三医院泌尿外科采用1 470 nm激光治疗共89例高危前列腺增生患者的临床资料,年龄平均(68±3)岁,前列腺体积(57.4±2.6)ml。所有患者均采用"寻找层面,先易后难,剜切结合"的层面递进法思路行激光腔内前列腺剜除术,比较患者术中及术后情况。
结果89例均顺利完成手术,与术前相比,术后3个月患者最大尿流率明显增加,[(6.9±2.1) ml/s vs(19.8±3.6) ml/s]。国际前列腺症状评分显著好转,[(24.6±1.7) vs(8.0±1.2)]。术中无输血、无电切综合征、无直肠和膀胱穿孔病例,无输尿管损伤、大出血、心脑血管意外等严重并发症发生。
结论层面递进法激光剜除技术构想对于高危前列腺增生外科包膜层面的寻找、减少术后并发症有独到优势,且易于掌握,或可为业界同行提供一个新的思路。 相似文献
23.
24.
目的:评价萸竹定眩丸对痰浊阻络型眩晕的治疗效果及对外周血FGF-21水平的影响。方法:120例患者随机分为治疗组和对照组,对照组口服盐酸氟桂利嗪胶囊10mg,每晚1次;治疗组在对照组的基础上给予萸竹定眩丸,每次1丸,每日2次;两组均治疗14天。14天后比较两组患者临床疗效、血脂及外周血中FGF-21水平。结果:治疗组总有效率为93. 3%,对照组总有效率为66. 7%,两组总有效率比较有统计学差异(P 0. 05);治疗后两组FGF-21水平均较治疗前明显降低(P 0. 01,P 0. 05),且治疗组FGF-21水平比对照组降低更明显(P 0. 05);治疗后,两组的TC、TG、LDL-C水平均较治疗前明显下降,HDL-C水平均较治疗前明显升高(P 0. 01),且治疗组的TC水平比对照组下降更显著,HDL-C水平比对照组上升更显著(P 0. 01)。结论:萸竹定眩丸治疗椎-基底动脉供血不足性眩晕(中医辨证属痰浊阻络型眩晕)具有明确疗效;萸竹定眩丸对改善人体的糖脂代谢水平,降低TC,升高HDL-C疗效明确;萸竹定眩丸在临床应用中未发现严重不良反应,临床应用安全可靠。 相似文献
25.
26.
Qianlai Luo Jonathan N. Hofmann Ruth M. Pfeiffer Cari M. Kitahara Minkyo Song Meredith S. Shiels 《International journal of cancer. Journal international du cancer》2023,153(1):64-72
In the United States, renal cell carcinoma (RCC) incidence and the prevalence of obesity, an established risk factor for RCC, have been increasing for several decades. RCC is more common among older individuals. We sought to quantify the contribution of excess adiposity to the rising incidence of RCC among individuals 60 years or older. National Institutes of Health-American Association of Retired Persons Diet and Health Study data (n = 453 859 participants, enrolled in 1995-1996, age at enrollment 50-71 years) were used to estimate multivariable-adjusted hazard ratios (HRs) for RCC across body mass index categories and HRs associated with smoking. Population attributable fractions (PAFs) were calculated using estimated HRs and annual overweight/obesity prevalence from the National Health Interview Survey (1985-2008). PAF estimates were combined with RCC incidence from Surveillance, Epidemiology and End Results-13 to calculate annual percent changes in RCC incidence attributable (and unrelated) to overweight/obesity. We found that between 1995 and 2018, among individuals aged 60 years and older, PAF for overweight/obesity increased from 18% to 29% for all RCCs. In comparison, the PAF for smoking declined from 12% to 9%. RCC incidence increased 1.8% per year (95% confidence interval [CI] 1.5%-2.1%) overall, while RCC incidence attributable to overweight/obesity increased 3.8% per year (95%CI 3.5%-4.2%) and RCC incidence unrelated to overweight/obesity increased 1.2% per year (95% CI 0.9%-1.4%). In conclusion, overweight/obesity appears to have contributed importantly to the rising incidence of RCC in the United States since the mid-1990s. Public health interventions focused on reducing overweight and obesity could help substantially in curbing this trend. 相似文献
27.
28.
29.
30.
Yi Li Ying Chen Xiang Li Jian Wu Jing-Ying Pan Ri-Xin Cai Ri-Yun Yang Xiao-Dong Wang 《中国神经再生研究》2019,(9)
In the search for a therapeutic schedule for spinal cord injury, it is necessary to understand key genes and their corresponding regulatory networks involved in the spinal cord injury process. However, ad hoc selection and analysis of one or two genes cannot fully reveal the complex molecular biological mechanisms of spinal cord injury. The emergence of second-generation sequencing technology(RNA sequencing) has provided a better method. In this study, RNA sequencing technology was used to analyze differentially expressed genes at different time points after spinal cord injury in rat models established by contusion of the eighth thoracic segment. The numbers of genes that changed significantly were 944, 1362 and 1421 at 1, 4 and 7 days after spinal cord injury respectively. After gene ontology analysis and temporal expression analysis of the differentially expressed genes, C5ar1, Socs3 and CCL6 genes were then selected and identified by real-time polymerase chain reaction and western blot assay. The mRNA expression trends of C5ar1, Socs3 and CCL6 genes were consistent with the RNA sequencing results. Further verification and analysis of C5ar1 indicate that the level of protein expression of C5ar1 was consistent with its nucleic acid level after spinal cord injury. C5ar1 was mainly expressed in neurons and astrocytes. Finally, the gene Itgb2,which may be related to C5ar1, was found by Chilibot database and literature search. Immunofluorescence histochemical results showed that the expression of Itgb2 was highly consistent with that of C5ar1. Itgb2 was expressed in astrocytes. RNA sequencing technology can screen differentially expressed genes at different time points after spinal cord injury. Through analysis and verification, genes strongly associated with spinal cord injury can be screened. This can provide experimental data for further determining the molecular mechanism of spinal cord injury, and also provide possible targets for the treatment of spinal cord injury. This study was approved ethically by the Laboratory Animal Ethics Committee of Jiangsu Province, China(approval No. 2018-0306-001) on March 6, 2018. 相似文献